Last updated on June 2017

A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)


Brief description of study

This is an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study will allow dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose will be based on the subject's dose at the end of the TRA115450 study. The maximum dose will be 75 mg daily.

Clinical Study Identifier: NCT02201290

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novartis Pharmaceuticals

Novartis Investigative Site
Krasnodar, Russian Federation
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Moscow, Russian Federation
  Connect »

Novartis Pharmaceuticals

Novartis Investigative Site
Saint Petersburg, Russian Federation
  Connect »